LGND
Ligand Pharmaceuticals Incorporated·Healthcare
230.17
7.838%(+16.73)
Market OpenLast Updated: — ET
52W L: $98.8952W H: $231.56
LGND NEWS
globenewswire.com
7h ago
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.
defenseworld.net
1d ago
Analyzing Olema Pharmaceuticals (NASDAQ:OLMA) and Ligand Pharmaceuticals (NASDAQ:LGND)
Olema Pharmaceuticals (NASDAQ: OLMA - Get Free Report) and Ligand Pharmaceuticals (NASDAQ: LGND - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership. Earnings and Valuation This table compares Olema Pharmaceuticals
defenseworld.net
Apr 6
Aberdeen Group plc Lowers Stock Position in Ligand Pharmaceuticals Incorporated $LGND
Aberdeen Group plc cut its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 37.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 119,309 shares of the biotechnology company's stock after selling 70,439 shares during the period. Aberdeen Group plc
defenseworld.net
Apr 6
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among analysts
defenseworld.net
Apr 5
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells $94,441.41 in Stock
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report) Director John Kozarich sold 467 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $202.23, for a total value of $94,441.41. Following the transaction, the director directly owned 42,253 shares in the company, valued at
defenseworld.net
Apr 3
Ligand Pharmaceuticals (NASDAQ:LGND) Insider Andrew Reardon Sells 5,000 Shares
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report) insider Andrew Reardon sold 5,000 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $201.24, for a total value of $1,006,200.00. Following the transaction, the insider directly owned 41,382 shares in the company, valued at approximately
